专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2197858A2 1,3,5-TRIAZINE-2,4,6-TRIAMINE COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 有权
标题翻译： 1,3,5-三嗪-2,4,6-三胺或它们的药学上可接受的盐和药物组合物中以
公开(公告)号：EP2197858A2
公开(公告)日：2010-06-23
申请号：EP08793562.3
申请日：2008-08-28
申请人： Hanall Pharmaceutical Company Ltd , Korea Research Institute Of Chemical Technology
发明人： CHEON, Hyae Gyeong , KIM, Kwang-Rok , RHEE, Sang Dal , JUNG, Won Hoon , LEE, Jong-Cheol , KIM, Sung Wuk , JUN, Sung Soo
IPC分类号： C07D251/54
CPC分类号： C07D251/70 , A61K31/53 , C07D251/54 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/12
摘要： Disclosed herein are a 1,3,5-triazine-2,4,6-triamine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for preventing or treating metabolic syndromes, diabetes, or cancers with deletion of P53 gene, which comprises the same.

2. 发明公开

EP2086519A1 CONTROLLED RELEASE COMPLEX COMPOSITION COMPRISING ANGIOTENSIN-II-RECEPTOR BLOCKERS AND HMG-COA REDUCTASE INHIBITORS 有权
标题翻译：具有血管紧张素-II-受体阻断剂和HMG-CoA还原酶抑制剂COMPLEX控释组合物
公开(公告)号：EP2086519A1
公开(公告)日：2009-08-12
申请号：EP07833713.6
申请日：2007-10-30
申请人： Hanall Pharmaceutical Company LTD.
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , SON, Jae Woon
IPC分类号： A61K9/22 , A61K31/00 , A61K9/48
CPC分类号： A61K31/00 , A61K9/2077 , A61K9/209
摘要： Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.

3. 发明公开

EP2203418A2 N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 有权
标题翻译： N，N-二甲基IMIDODICARBONIMID-DIAMID®二羧酸酯，用于生产它，所以药物组合物
公开(公告)号：EP2203418A2
公开(公告)日：2010-07-07
申请号：EP08832662.4
申请日：2008-09-19
申请人： Hanall Pharmaceutical Company Ltd
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Young Woong , KIM, Byoung Ha , KIM, Duck
IPC分类号： C07C279/26
CPC分类号： C07C279/26 , C07C55/08 , C07C55/12 , C07C55/14 , C07C59/245
摘要： Disclosed herein are a novel dicarboxylic acid salt of N,N- dimethylimidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are a novel dicarboxylic acid salt of N,N- dimethylimidodicarbonimidic diamide, a crystalline acid addition salt prepared by allowing N,N-dimethylimidodicarbonimidic diamide to react with a specific dicarboxylic acid, which has improved physical and chemical properties including solubility, stability, non-hygroscopicity and anti-adhesive properties, and low toxicity, and thus is very effective in the prevention and treatment of not only diabetes and its complications in patients with so-called metabolic syndromes, in which diabetes, obesity, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndromes, etc. appear in combination, but also p53 gene-deficient cancers, muscular pain, muscle cytotoxicity and rhabdomyolysis, as well as a preparation method thereof and a pharmaceutical composition comprising the same.
摘要翻译：公开在是N的新颖的二羧酸盐，N- dimethylimidodicarbonimidic二酰胺，它们的制备方法和包含其的药物组合物。更具体地，在游离缺失盘是N，N-二dimethylimidodicarbonimidic二酰胺，通过使N，N-二dimethylimidodicarbonimidic二酰胺与特定的二羧酸，其具有改善的物理和化学性质，包括溶解度反应制备的结晶酸加成盐的新的二羧酸盐，稳定性，非吸湿性和抗粘接性，低毒性，因而不仅在糖尿病及其并发症的预防和治疗的患者所谓代谢综合征非常有效，其中的糖尿病，肥胖症，高脂血症，脂肪肝，冠状动脉疾病，骨质疏松症，多囊性卵巢综合征等出现在组合，所以但p53基因缺陷型癌症，肌肉疼痛，肌肉细胞毒性和横纹肌溶解，以及它们的制备方法和包含其的药物组合物。

4. 发明公开

EP2109447A1 N, N- DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 失效转让
标题翻译： N，N-二甲基IMIDODICARBONIMID-DIAMID®醋酸酯，方法才能产生与药物组合物
公开(公告)号：EP2109447A1
公开(公告)日：2009-10-21
申请号：EP08712220.6
申请日：2008-01-29
申请人： Hanall Pharmaceutical Company LTD.
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Young Woong
IPC分类号： A61K31/155
CPC分类号： A61K31/155 , C07C279/26
摘要： The present invention relates to N,N -dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc., and low toxicity, a method of preparing the same and a pharmaceutical composition comprising the same.

5. 发明公开

EP2079452A1 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING THIAZIDES AND ANGIOTENSIN-II-RECEPTOR BLOCKERS 审中-公开
标题翻译：噻嗪类利尿剂和血管紧张素II受体拮抗剂药物组合物具有控释
公开(公告)号：EP2079452A1
公开(公告)日：2009-07-22
申请号：EP07833711.0
申请日：2007-10-30
申请人： Hanall Pharmaceutical Company LTD.
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Jin Wook , SON, Jae Woon
IPC分类号： A61K9/22 , A61K31/00 , A61K9/48
CPC分类号： A61K31/00 , A61K9/2086 , A61K9/209 , A61K31/549 , A61K45/06 , A61K2300/00
摘要： Disclosed herein is a pharmaceutical composition, containing a thiazide compound and an angiotensin-II-receptor blocker, and a technology for formulating the same. More particularly, disclosed is a pharmaceutical combination formulation of thiazide compound and angiotensin-II-receptor blocker, which maximizes the pharmacological and clinical antihypertensive effects and complication preventive effects of the drugs and reduces the side effects of the drugs, compared to when single-component formulations of the drugs are administered simultaneously.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式